CHLORPROMAZINE HYDROCHLORIDE

Post-LOE

chlorpromazine hydrochloride

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Jul 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CHLORPROMAZINE HYDROCHLORIDE (chlorpromazine hydrochloride) by Pfizer is clinical pharmacology the precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. Approved for schizophrenia. First approved in 2020.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. The principal pharmacological actions are psychotropic. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous…

Indications (1)

schizophrenia

Clinical Trials (1)

NCT02943213Phase 1Completed

Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

Started Nov 2016

20 enrolled

Anti-PsychoticManagement of Manifestations of Psychotic DisordersTreatment of Schizophrenia+6 more

Worked on CHLORPROMAZINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.